Albert F. Lobuglio
#148,689
Most Influential Person Now
Albert F. Lobuglio's AcademicInfluence.com Rankings
Albert F. Lobugliophilosophy Degrees
Philosophy
#8122
World Rank
#11445
Historical Rank
Logic
#5154
World Rank
#6529
Historical Rank

Albert F. Lobugliobiology Degrees
Biology
#10965
World Rank
#14331
Historical Rank
Immunology
#697
World Rank
#719
Historical Rank

Download Badge
Philosophy Biology
Albert F. Lobuglio's Degrees
- Doctorate Medicine University of California, San Francisco
- PhD Immunology Stanford University
Why Is Albert F. Lobuglio Influential?
(Suggest an Edit or Addition)Albert F. Lobuglio's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. (1999) (893)
- Role of hydrogen peroxide in neutrophil-mediated destruction of cultured endothelial cells. (1981) (565)
- Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. (1989) (545)
- Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. (2001) (493)
- Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. (2004) (489)
- Red Cells Coated with Immunoglobulin G: Binding and Sphering by Mononuclear Cells in Man (1967) (437)
- Human Blood Monocytes: Stimulators of Granulocyte and Mononuclear Colony Formation in vitro (1972) (366)
- Human immune response to monoclonal antibodies. (1994) (303)
- Effects of corticosteroid therapy on human monocyte function. (1975) (246)
- Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. (2000) (236)
- The Small Heat Shock Protein αB-crystallin Is a Novel Inhibitor of TRAIL-induced Apoptosis That Suppresses the Activation of Caspase-3* (2005) (230)
- Effects of corticosteroids on human monocyte function. (1974) (222)
- Characterization of a messenger RNA polynucleotide vaccine vector. (1995) (219)
- Nuclear Localization of KLF4 Is Associated with an Aggressive Phenotype in Early-Stage Breast Cancer (2004) (211)
- A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. (2001) (208)
- Expression of human endogenous retrovirus k envelope transcripts in human breast cancer. (2001) (174)
- Human granulocyte generation of hydroxyl radical (1978) (168)
- Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. (1997) (167)
- Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. (2000) (161)
- A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. (2000) (150)
- CD16+ monocytes in patients with cancer: spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor. (1995) (149)
- Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. (2003) (146)
- Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. (2002) (145)
- Immune response to a carcinoembryonic antigen polynucleotide vaccine. (1994) (144)
- Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. (2004) (140)
- Cellular Model of Warburg Effect Identifies Tumor Promoting Function of UCP2 in Breast Cancer and Its Suppression by Genipin (2011) (137)
- Recurrent read-through fusion transcripts in breast cancer (2014) (137)
- Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response. (1988) (133)
- Evidence for hydroxyl radical generation by human Monocytes. (1977) (132)
- A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. (1995) (130)
- A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. (2003) (129)
- Selected strategies to augment polynucleotide immunization. (1996) (128)
- Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. (1993) (125)
- Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. (1994) (121)
- Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. (1992) (119)
- Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. (1996) (114)
- A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. (2002) (110)
- A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. (2002) (99)
- A Sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expression in vivo. (1995) (97)
- Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. (1999) (97)
- Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects. (1988) (96)
- Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody. (1991) (96)
- Leukemic reticuloendotheliosis. A study of the origin of the malignant cell. (1975) (96)
- The nature of the alpha-methyldopa red-cell antibody. (1967) (95)
- Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes (2016) (94)
- Immune thrombocytopenic purpura. Use of a 125I-labeled antihuman IgG monoclonal antibody to quantify platelet-bound IgG. (1983) (91)
- Characterization of glass adherent human mononuclear cells. (1973) (89)
- A potential role for hypochlorous acid in granulocyte-mediated tumor cell cytotoxicity. (1980) (88)
- Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. (2006) (87)
- Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. (2001) (86)
- An antibody cytotoxic to megakaryocyte progenitor cells in a patient with immune thrombocytopenic purpura. (1985) (85)
- An oxygen-dependent mechanism of neutrophil-mediated cytotoxicity. (1980) (84)
- Drug therapy of autoimmune hemolytic anemia. (1976) (83)
- Phagocyte-generated oxygen metabolites and cellular injury. (1982) (81)
- Human monocyte, lymphocyte, and granulocyte antibody-dependent cell-mediated cytotoxicity toward tumor cells. I. General characteristics of cytolysis. (1979) (80)
- Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine. (2000) (79)
- A carcinoembryonic antigen polynucleotide vaccine for human clinical use. (1995) (77)
- Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. (1992) (76)
- Effect of Niclosamide on Basal-like Breast Cancers (2014) (74)
- Immunologic specificity of transfer factor. (1974) (73)
- Alterations in hexose monophosphate shunt during lymphoblastic transformation. (1974) (72)
- Mouse/human chimeric antibodies to a tumor-associated antigen: biologic activity of the four human IgG subclasses. (1988) (71)
- Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy. (2002) (71)
- Characterization of a mouse/human chimeric monoclonal antibody (17-1A) to a colon cancer tumor-associated antigen. (1987) (70)
- Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function. (2006) (67)
- Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. (1999) (67)
- Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. (2001) (66)
- ING-1, a Monoclonal Antibody Targeting Ep-CAM in Patients with Advanced Adenocarcinomas (2004) (66)
- Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. (2005) (66)
- Human monocyte antibody-dependent cell-mediated cytotoxicity to tumor cells. (1978) (65)
- Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. (1996) (63)
- Oxidative mechanisms of monocyte-mediated cytotoxicity. (1980) (63)
- Cetuximab Augments Cytotoxicity with Poly (ADP-Ribose) Polymerase Inhibition in Head and Neck Cancer (2011) (61)
- Generation of a human anti-idiotypic antibody that mimics the GD2 antigen. (1993) (59)
- Polynucleotide-mediated immunization therapy of cancer. (1996) (59)
- Human monocyte cytotoxicity to tumor cells. I. Antibody-dependent cytotoxicity. (1978) (58)
- Decreased Serum B12 Levels With Oral Contraceptive Use (1972) (57)
- Phase I Trial of an Anti‐CD19 Deglycosylated Ricin A Chain Immunotoxin in Non‐Hodgkin's Lymphoma: Effect of an Intensive Schedule of Administration (1995) (56)
- Ultrastructural analysis of human natural killer cell activation. (1987) (53)
- HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair. (2012) (52)
- Phase I Study of the Intratumoral Administration of Recombinant Canarypox Viruses Expressing B7.1 and Interleukin 12 in Patients with Metastatic Melanoma (2005) (50)
- Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. (2007) (50)
- Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer. (1995) (49)
- Phase I Study of a Plasmid DNA Vaccine Encoding MART-1 in Patients with Resected Melanoma at Risk for Relapse (2005) (49)
- Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome. (1990) (48)
- Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma (2013) (47)
- Colchicine therapy for refractory idiopathic thrombocytopenic purpura. (1984) (47)
- History of antibody therapy for non-Hodgkin's lymphoma. (2003) (46)
- Tumor associated glycoprotein-72 is highly expressed in prostatic adenocarcinomas. (1994) (46)
- TRAIL receptor-targeted therapy. (2006) (44)
- Characterization of poliovirus replicons encoding carcinoembryonic antigen. (1994) (44)
- TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth (2007) (42)
- Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma. (2005) (42)
- Transfer factor: isolation of a biologically active component. (1973) (41)
- The effect of transfer factor therapy on tumor immunity in alveolar soft part sarcoma. (1973) (40)
- Immune function of successfully treated lymphoma patients. (1976) (40)
- Evidence for the elevation of serum carcinoembryonic antigen and tumor-associated glycoprotein-72 levels in patients administered interferons. (1991) (39)
- Quantification of platelet-bound IgG by 125I-Staphylococcal protein A in immune thrombocytopenic purpura and other thrombocytopenic disorders. (1984) (38)
- Brief Overview of Preclinical and Clinical Studies in the Development of Intraperitoneal Radioimmunotherapy for Ovarian Cancer (2007) (37)
- Epithelial transformation by KLF4 requires Notch1 but not canonical Notch1 signaling (2009) (37)
- Human lymphocyte, monocyte, and neutrophil antibody-dependent cell-mediated cytotoxicity toward human erythrocytes. (1978) (36)
- Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen. (1998) (36)
- Treatment of Human Colon Cancer Xenografts with TRA-8 Anti-death Receptor 5 Antibody Alone or in Combination with CPT-11 (2008) (34)
- Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein. (2005) (33)
- A novel monoclonal antibody design for radioimmunotherapy. (2003) (33)
- Juvenile "congenital" pernicious anemia. Clinical and immunologic studies. (1966) (33)
- Phase I study of anti-epidermal growth factor receptor (anti-EGFR) antibody C225 in combination with irradiation in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) (1998) (32)
- The effect of tuberculosis and neoplasia on human monocyte staphylocidal activity. (1975) (32)
- Monocyte-mediated antibody-dependent cell-mediated cytotoxicity: the role of the metabolic burst. (1981) (31)
- TRAIL-receptor antibodies as a potential cancer treatment. (2007) (31)
- A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1. (1993) (30)
- Hedgehog Pathway Expression in Heterogeneous Pancreatic Adenocarcinoma: Implications for the Molecular Analysis of Clinically Available Biopsies (2007) (30)
- Advances in monoclonal antibody therapy of cancer. (1992) (30)
- Phase I clinical trial of CO17-1A monoclonal antibody. (1986) (30)
- Measurement of Platelet Surface‐Bound IgG by a Monoclonal 125I‐Anti‐IgG Assay (1986) (29)
- Recent progress in radioimmunotherapy for cancer. (1997) (29)
- Platelet surface-bound IgG in patients with immune and nonimmune thrombocytopenia. (1987) (29)
- Human lymphocyte antibody-dependent cell-mediated cytotoxicity (ADCC) toward human red blood cells. (1978) (28)
- Intraperitoneal Pretarget Radioimmunotherapy with CC49 Fusion Protein (2005) (28)
- Radioimmunoassay of free β-subunit of human chorionic gonadotropin as a prognostic test for persistent trophoblastic disease in molar pregnancy (1986) (28)
- Induction of anti‐tumor immunity by intrasplenic administration of a carcinoembryonic antigen DNA vaccine (2000) (27)
- Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity (2012) (27)
- Sarcoid lymphocytes: spontaneous transformation and release of macrophage migration inhibition activity. (1976) (27)
- Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration. (2005) (26)
- A review of transfer factor immunotherapy in cancer (1974) (26)
- CD 16 + Monocytes in Patients With Cancer : Spontaneous Elevation and Pharmacologic Induction by Recombinant Human Macrophage Colony-Stimulating Factor (2000) (25)
- Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. (1995) (25)
- Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region. (2005) (24)
- Monocyte-platelet interaction in immune and nonimmune thrombocytopenia. (1989) (24)
- Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in three phase II clinical trials. (1997) (24)
- A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer. (1993) (23)
- SARCOID LYMPHOCYTES: B‐ AND T‐CELL QUANTITATION (1976) (22)
- Human monocyte killing of Staphylococcus aureus: modulation by agonists of cyclic adenosine 3',5'-monophosphate and cyclic guanosine 3',5'-monophosphate (1979) (22)
- In vivo treatment with a monoclonal chimeric anti‐CD4 antibody results in prolonged depletion of circulating CD4+ cells in chimpanzees (1993) (22)
- Chemotherapy of intermediate- and high-grade non-Hodgkin's lymphomas with a high-dose doxorubicin-containing regimen. (1990) (21)
- Editorial: Leukemic reticuloendotheliosis: a defined syndrome of an ill defined cell. (1976) (21)
- Effect of TRA-8 Anti-Death Receptor 5 Antibody in Combination With Chemotherapy in an Ex Vivo Human Ovarian Cancer Model (2009) (20)
- Phytomitogen- and antigen-induced blast transformation of feline lymphocytes. (1975) (20)
- PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers (2015) (20)
- A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma. (2006) (20)
- HUMAN IMMUNE RESPONSE TO CARCINOEMBRYONIC ANTIGEN TUMOR VACCINES (1995) (19)
- A migration inhibition-factor assay for tumor immunity in man. (1973) (19)
- Direct quantitation of IgG subclasses 1, 2, and 3 bound to red cells by Rh1 (D) antibodies (1988) (18)
- Clustered IgG on human red blood cell membranes may promote human lymphocyte antibody-dependent cell-mediated cytotoxicity. (1980) (18)
- Platelet surface-bound IgG in patients with immune and nonimmune thrombocytopenia (1987) (18)
- Clinical use of a standard kit-preparation of radiolabeled monoclonal antibody 96.5 in the diagnostic imaging of metastatic melanoma. (1988) (18)
- Griffonia simplicifolia I lectin mediates macrophage-induced cytotoxicity against Ehrlich ascites tumor. (1982) (18)
- Combination chemotherapy of refractory lymphoma with cis‐dichlorodiamineplatinum, vinblastine, and bleomycin (1982) (17)
- Comparison of diagnostic and therapeutic doses of 131I-LYM-1 in patients with non-Hodgkin's lymphoma (1993) (17)
- Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma (2007) (17)
- Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cells. (1998) (16)
- Immune Hemolytic anemia. (1980) (16)
- Re-examination of the EA rosette assay (Ripley) for Fc receptor leucocytes. (1979) (16)
- Comparison of two mouse/human chimeric antibodies in patients with metastatic colon cancer (1992) (16)
- Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy. (2003) (15)
- Human monocyte glucose metabolism in lymphoma. (1977) (14)
- The monocyte: new concepts of function. (1973) (14)
- Decreased serum B 12 levels with oral contraceptive use. (1972) (14)
- Neoantigen response in patients successfully treated for lymphoma. A Southwest Oncology Group study. (1979) (13)
- Phytohemagglutinin (PHA) skin test in patients with sarcoidosis. (1975) (13)
- An Oxygen-Dependent Mechanism of Neutrophil-Mediated Cytotoxicity (1980) (13)
- Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer. (2012) (13)
- Human lymphocyte and monocyte lysis of tumor cells mediated by a mouse/human IgG1 chimeric monoclonal antibody. (1988) (12)
- Effect of intravenous gammaglobulin on circulating and platelet-bound antibody in immune thrombocytopenia (1989) (12)
- Effect of human immune response on repeat courses of 131-chimeric B72.3 antibody therapy (1993) (12)
- Monoclonal antibody therapy of cancer. (1992) (12)
- Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rhM-CSF) in patients with metastatic gastrointestinal cancer. (1995) (12)
- Etretinate therapy for psoriasis. Reduction of antibody-dependent cell-mediated cytotoxicity of polymorphonuclear leukocytes. (1985) (12)
- Treatment of hypercalcemia associated with malignancy. (1978) (12)
- Skin test conversion following transfer factor. A double-blinded study of normal individuals. (1978) (11)
- Quantitative assay of a human monoclonal IgM antibody (HA-1A) in human serum. (1989) (11)
- Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition (2014) (11)
- Identification of hypoxanthine as the major compoenet of a chromatographic fraction of transfer factor. (1976) (10)
- Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma. (2011) (10)
- Human monocyte interaction with antibody‐coated platelets. I. General characteristics (1984) (10)
- SEREX analysis for tumor antigen identification in a mouse model of adenocarcinoma (2000) (10)
- High-dose adriamycin combination chemotherapy for intermediate and high-grade non-Hodgkin's lymphomas. (1985) (10)
- Transfer factor: a potential agent for cancer therapy. (1976) (10)
- Impact of Rituximab Treatment on 90Y-Ibritumomab Dosimetry for Patients with Non-Hodgkin Lymphoma (2010) (10)
- Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapy. (2003) (9)
- Suppression of human anti-mouse antibody response to murine monoclonal antibody L6 by deoxyspergualin: a phase I study. (1994) (9)
- Pharmacokinetics of a Mouse/Human Chimeric Monoclonal Antibody (C-17-1 A) in Metastatic Adenocarcinoma Patients (1990) (9)
- A Method to Correct for Radioactivity in Large Vessels That Overlap the Spine in Imaging-Based Marrow Dosimetry of Lumbar Vertebrae (2008) (9)
- Frequent anti-V-region immune response to mouse B72.3 monoclonal antibody (1992) (9)
- Phase 1 trial of a novel anti-CD 20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma (2004) (8)
- A non-invasive approach for monitoring breast tumor cells during therapeutic intervention. (2002) (8)
- Comparison of monocyte and alveolar macrophage antibody-dependent cellular cytotoxicity and Fc-receptor activity. (1981) (8)
- Chemotherapy tolerance after radioimmunotherapy with 90Y-CC49 monoclonal antibody in patients with advanced non-small cell lung cancer: clinical effects and hematologic toxicity. (2003) (8)
- Phase I Trial of the Murine Monoclonal Anti-GD 2 Antibody 14 G 2 a in Metastatic Melanoma 1 (2006) (8)
- Development and characterization of a monoclonal antibody to human embryonal carcinoma. (1987) (7)
- Immune thrombocytopenia: effects of maternal gamma globulin infusion on maternal and fetal serum, platelet, and monocyte IgG. (1987) (7)
- Study of the malarial parasite-red cell relationship with the use of a new immunologic marker. (1971) (7)
- Radioimmunoscintigraphic detection of occult gestational choriocarcinoma. (1987) (7)
- Normal human monocytes inhibit tumor cell growth in vitro. (1978) (6)
- Lack of T-cell immunity in humans with preexisting anti-mouse immunoglobulin reactivity. (1992) (6)
- Human monocyte metabolism: male vs. female. (1975) (6)
- IDENTIFICATION OF HYPOXANTHINE AS THE MAJOR COMPONENT OF CHROMATOGRAPHICALLY PREPARED TRANSFER FACTOR (1976) (6)
- Interaction of monocytes with tumor cells coated with complement with or without antibody. (1980) (6)
- Correlation of prognostic factors and blood lymphocyte subtypes in non‐Hodgkin's lymphoma (1980) (5)
- Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy. (2006) (5)
- Effect of mouse anti-I region antiserum and complement on human mononuclear cell response to concanavalin A. (1982) (5)
- Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity. (2006) (5)
- Etretinate therapy and immune activities. (1986) (5)
- Quinidine-induced immune thrombocytopenia. (1989) (5)
- Radioimmunotherapy of colon cancer with an improved humanized monoclonal antibody design (2002) (5)
- TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer (2020) (5)
- Human Monocyte Antibody-Dependent Cell-Mediated (1978) (5)
- Phagocytosis of technetium-99m sulfur colloid by human polymorphonuclear leukocytes. (1978) (4)
- Effect of intravenous gammaglobulin on circulating and platelet-bound antibody in immune thrombocytopenia. (1989) (4)
- Detection of human anti-murine antibody (HAMA) following infusion of Oncoscint® CR103 : comparison of Immustrip® ELISA with a double antigen radiometric assay (1991) (4)
- ln-111 Labeled Monoclonal Anti-Carcinoembryonic Antigen Antibody (ZCE025) in the Immunoscintigraphlc Imaging of Metastatic Antigen-Producing Adenocarcinomas (1991) (4)
- Chimeric antibodies. (1993) (4)
- Phase II trial of Baker's antifol in metastatic renal cell carcinoma: a Southwest Oncology Group Study. (1980) (4)
- Long Term Outcome of Intraperitoneal Radioimmunotherapy for Ovarian Cancer (2008) (4)
- Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma. (2013) (3)
- Transfer-factor therapy of malignancy. (1974) (3)
- Leukopenia -- a new immune mechanism. (1976) (3)
- radioimmunotherapy for B-cell non-Hodgkin's lymphoma Phase I trial of a novel anti-CD20 fusion protein in pretargeted (2013) (3)
- Testicular uptake and radiation dose in patients receiving Zevalin and Pretarget CC49Fusion protein. (2005) (3)
- Genetic Immunotherapy Approaches (2005) (3)
- Immunoperoxidase staining of early human melanoma colonies with monoclonal antibodies. A new method for in vitro antigenic-morphologic correlation. (1984) (3)
- MHC II antigen presentation pathway expression in triple-negative breast cancer. (2015) (3)
- Chimeric antibodies with specificity for tumor antigens: demonstration of in situ localization to tumors after antibody therapy. (1998) (3)
- Lymphocyte sensitivity and cellular immunity in neoplasia. (1973) (3)
- Human tumor-specific immunity--has it "arrived"? (1993) (2)
- Transfer factor: Potential for therapy of malignant diseases. (1975) (2)
- TBCRC 002: A phase II, randomized, open label trial of preoperative letrozole versus letrozole (LET) in combination with bevacizumab (BEV) in post-menopausal women with newly diagnosed stage II/III breast cancer. (2013) (2)
- Susceptibility of HER2+ breast cancer cells to poly (ADP-ribose) polymerase (PARP) inhibition independent of an inherent DNA repair defect. (2012) (2)
- Fractionated radioimmunotherapy FOR PATIENTS WITH CHEMOTHERAPY-RESISTANT NON-HODGKINS LYMPHOMA (NHL) (1992) (2)
- A Pilot Trial of Pre-Operative (Neoadjuvant) Letrozole in Combination with Bevacizumab in Post-Menopausal Women with Newly Diagnosed Estrogen and/or Progesterone Receptor Positive Breast Cancer. (2009) (2)
- Clinical Experience with Murine, Human and Genetically Engineered Monoclonal Antibodies (1994) (2)
- Effects of Adjuvant Chelator or Chemotherapy on Dosimetry of 90Y-CC49 in Lung Cancer Patients Using 111In-CC49 as a Tracer (2004) (2)
- Brentuximab Vedotin (SGN-35) for CD30-Positive Malignancies (2013) (2)
- The expression of class II major histocompatibility molecules on breast tumors delays T cell exhaustion, expands the T cell repertoire and slows tumor growth (2018) (2)
- Targeting of 125I-Labeled B Lymphocyte Stimulator (2003) (2)
- Synthetic Lethal Interactions Between EGFR and PARP Inhibition in Triple Negative Breast Cancer (2012) (1)
- INTRATUMORAL INJECTION OF A CANARYPOX VIRUS ENCODING HUMAN (ALVAC-IL-12) IN MELANOMA PATIENTS: RESULTS OF A PHASE Ib TRIAL (1999) (1)
- Human Immune Respone to Monoclonal Antibodies (1994) (1)
- CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE) (2013) (1)
- Phase 1 study of an anti-GD3 monoclonal antibody, (KW-2871) in patients with advanced metastatic melanoma (2005) (1)
- Immune response to L2 guinea pig leukemia-specific antigens. (1977) (1)
- 2125 Enhanced intraperitoneal radioimmunotherapy with adjuvant Interferon and Taxol (1997) (1)
- THE ABILITY OF THE LATEX-BINDING LYMPHOCYTE ASSAY TO PREDICT IN VIVO EFFICACY OF ANTILYMPHOCYTE SERA (1972) (1)
- Radioimmunotherapy for metastatic prostate cancer using a high affinity antibody (1993) (1)
- Abstract P1-12-04: Long Term Follow-Up of a Pilot Trial of Pre-Operative (Neoadjuvant) Letrozole in Combination with Bevacizumab in Post-Menopausal Women with Newly Diagnosed Estrogen and/or Progesterone Receptor Positive Breast Cancer (2010) (1)
- 503 Phase I radioimmunotherapy (RIT) study of 90Y-CC49 monoclonal antibody (MAb) therapy in patients with advanced non-small cell lung cancer (NSCLC) (1997) (1)
- LOW V-REGION IMMUNOGENICITY OF THERAPEUTIC DOSES OF 131I-LL2 MOUSE MONOCLONAL ANTIBODY IN LYMPHOMA PATIENTS (1994) (1)
- Safety and effectiveness of dose dense neoadjuvant chemotherapy in patients with stage II/III breast cancer. (2009) (1)
- Long-term follow-up of dose-dense neoadjuvant chemotherapy in patients with stage II/III breast cancer. (2011) (1)
- Alternated versus syncopated CHOP-PVB: two studies for the treatment of non-Hodgkin's lymphoma by the Southwest Oncology Group. (1991) (1)
- Oxidative mechanisms of monocyte-mediated cytotoxicity ( phorbol myristate acetate / leukocytes / hydrogen peroxide / superoxide anion / superoxide dismutase ) (2003) (1)
- Human Monocyte Cytotoxicity to Tumor Cells (1978) (1)
- Effect of TRA-8 anti-DR5 monoclonal antibody in combination with chemotherapy in an ex vivo human ovarian cancer model (2008) (1)
- Treatment of metastatic colon cancer with fractionated dosing of radiolabeled monoclonal antibodies (1991) (1)
- An animal model to predict the immunogenicity of murine V regions in humans. (1993) (1)
- antibodies anti-DR5 combinations and anti-DR4 antibodies and other therapeutic agents (2002) (0)
- Traitement de cancers a genotype de type basal (2010) (0)
- Phase I T rial o f t he A nti-Lewis Y D rug I mmunoconjugate BR96-Doxorubicin i n P atients W ith L ewis Y -Expressing Epithelial T umors (2000) (0)
- Therapeutics , Targets , and Chemical Biology HER 2 Overexpression Renders Human Breast Cancers Sensitive to PARP Inhibition Independently of Any Defect in Homologous Recombination DNA Repair (2012) (0)
- Abstract 4030: Epigenetic induction of MHC-II pathway expression in murine ovarian cancer cell line (2016) (0)
- Abstract P1-15-02: Long term follow-up of the neo-adjuvant pilot trial evaluating activity of letrozole in combination with bevacizumab in post-menopausal women with newly diagnosed estrogen and/or progesterone receptor positive primary breast cancer (2013) (0)
- Abstract P4-11-04: The Influence of Radiation on Survival in Patients with Triple Negative Stage II Breast Cancer (2010) (0)
- 2761 – A NEW ASSAY FOR ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) BY HUMAN LYMPHOCYTES (Ly), MONOCYTES (Mo) AND NEUTROPHILS (Ne) (1978) (0)
- Comparative dosimetry with repeat courses of 131I-labeled murine or mouse/human chimeric monoclonal antibodies (1990) (0)
- Protein in Patients with Gastrointestinal Malignancies Patient-Specific Dosimetry of Pretargeted Radioimmunotherapy Using CC 49 Fusion (2005) (0)
- Prediction of in vivo efficacy of antilymphocyte sera (ALS) by a new in vitro assay. (1971) (0)
- 189 PHASE 1 STUDY OF AN ANTI-GD3 MONOCLONAL ANTIBODY (KW-2871) IN PATIENTS WITH ADVANCED METASTATIC MELANOMA. (2006) (0)
- UAB-Community Breast Cancer Network (2002) (0)
- PHARMACOKINETICS AND IMMUNE RESPONSE OF 177LU-CC49 MONOCLONAL ANTIBODY IN PATIENTS WITH RECURRENT OR PERSISTENT OVARIAN CANCER (1994) (0)
- Abstract P5-10-19: The Influence of Time to Completion of Chemotherapy on Survival in Patients with Triple Negative Stage III Breast Cancer (2010) (0)
- Treatment of a B-Cell, Primary Central Nervous System Lymphoma Patient with Radioimmunotherapy Using Zevalin®: A Proof-of-Principal Case. (2004) (0)
- Monocyte antibody dependent cellular cyto toxicity to red blood cell targets competitive inhibition with immuno globulin g and immuno globulin g subclasses (1980) (0)
- Phase I Clinical and Pharmacological Study of Suppression of Human Antimouse Antibody Response to Monoclonal Antibody L 6 by Deoxyspergualin 1 (2006) (0)
- POLYNUCLEOTIDE IMMUNIZATION TO CEA VIA INTRAMUSCULAR INJECTION OR CUTANEOUS PARTICLE BOMBARDMENT (1995) (0)
- Technetium 99m labelling of corynebacterium parvum for study of tissue localization (1976) (0)
- Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody in prostate cancer (2002) (0)
- Impact of Full Dose of Rituximab on Pharmacokinetics and Dosimetry of Zevalin for Patients with Non-Hodgkin’s Lymphoma (2005) (0)
- Relevance of chemotherapy in gastrointestinal cancer. (1988) (0)
- IDENTIFICATION OF NOVEL TUMOR ASSOCIATED ANTIGENS IN MELANOMA PATIENTS RECEIVING ALVAC-IL-12 (1999) (0)
- TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer (2020) (0)
- Phase I, Multicenter, Open Label, Dose Escalation of 90 yttrium-Ibritumomab Tiuxetan Radioimmunotherapy Using a Modified Regimen for Relapsed or Refractory Follicular or Transformed CD20+ B-Cell Lymphoma (2011) (0)
- Abstract 4684: Synthetic lethal interaction between EGFR and PARP inhibition (2012) (0)
- 2105 Phase 1 trial of intraperitoneal radioimmunotherapy for ovarian cancer (1996) (0)
- Genetic insights into Warburg Effect reveal tumor promoting function of UCP2 (2011) (0)
- PROGRESS IN HEMATOLOGY, Vol. VI (1970) (0)
- Expression levels of PARP1 and phospho-p65 protein in human HER2-positive breast cancers. (2015) (0)
- Impact of rituximab treatment on Y-90-Zevalin dosimetry for patients with non-Hodgkin's lymphoma (2007) (0)
- A Preliminary Report of a Phase I Study of Zevalin® Using a Modified Treatment Regimen for Relapsed or Refractory CD20+ B-Cell Follicular or Transformed Non-Hodgkin’s Lymphoma (NHL). (2005) (0)
- Detection of disseminated breast cancer growth and treatment response using non-invasive bioluminescence imaging. (2004) (0)
- Abstract B37: Increased expression of poly (ADP-ribose) polymerase (PARP) and phospho-p65 in human HER2+ breast cancer (2013) (0)
- Crosstalk between PARP-1 and NF-κB signaling pathways as a potential determinant of PARPi sensitivity in trastuzumab resistant HER2+ breast cancer cell lines. (2015) (0)
- Erratum: Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region (Cancer Biotherapy and Radiopharmaceuticals (2005) 20, 5 (502-513)) (2005) (0)
- Limited sampling models for HA-1A IgM monoclonal antibody. (1990) (0)
- Invited commentary: targeting of 125I-labeled B lymphocyte stimulator. (2003) (0)
- EVIDENCE THAT RECOMBINANT INTERFERONS CAN ENHANCE THE SENSITIVITY OF THE DETECTION OF SERUM TAG-72 AND CEA IN PATIENTS DIAGNOSED WITH ADENOCARCINOMA (1992) (0)
- Biodistribution and Clearance of In-111/Y-90-IDEC-159 in Patients with Metastatic Colorectal Adenocarcinoma (2010) (0)
- Human HER2+ Breast Cancer Susceptibility to Poly(ADP-Ribose) Polymerase Inhibitors Independent of a Homologous Recombination Repair Defect (2012) (0)
- Abstract LB-260: Sensitivity of breast cancer stem cells to TRA-8 anti-DR5 monoclonal antibody (2010) (0)
- A new tumour marker for early detection of subclinical metastatic melanoma (2004) (0)
- Abstract 865: Inhibition of Wnt co-receptor LRP6 sensitizes basal-like breast cancer stem cells to TRA-8 anti-DR5 monoclonal antibody. (2013) (0)
- L2C leukemia: a model of human acute leukemia. (1977) (0)
- Survival predictors of intraperitoneal radioimmunotherapy for ovarian cancer (2011) (0)
- RITUXANTM/CHOP CHEMO IMMUNOTHERAPY IN PATIENTS WITH LOW-GRADE OR FOLLICULAR (LG/F) NON-HODGKINʼS LYMPHOMA (NHL) (1997) (0)
- IMMUNOGENICITY OF CHIMERIC MOUSE/HUMAN MONOCLONAL ANTIBODIES (1993) (0)
- Dendritic Cell Vaccine Therapy for Breast Cancer Micro-Metastases. (1995) (0)
- Intraperitoneal radioimmunotherapy for ovarian cancer: results of a phase i study with high affinity monoclonal antibody (1994) (0)
- Phase I Clinical and Pharmacological Study of Suppression of Human Antimouse Antibody Response to Monoclonal Antibody L6 by Deoxyspergualin1 (2006) (0)
- Treatment o f P atients W ith L ow-Grade B -Cell L ymphoma With t he C ombination o f C himeric A nti-CD20 M onoclonal Antibody a nd C HOP C hemotherapy (1999) (0)
- Safety and Immunogenicity of a DNA Vaccine Encoding Carcinoembryonic Antigen and Hepatitis B Surface Antigen in Colorectal Carcinoma Patients 1 (2002) (0)
- AN ANIMAL MODEL TO PREDICT THE IMMUNOGENICITY OF MURINE V-REGIONS IN MAN (1993) (0)
- Abstract 1461: MHCII-expressing breast cancer cells can induce anti-tumor immune response (2016) (0)
- Correlation between poly (ADP-ribose) polymerase (PARP) and phospho-p65 expression in human breast cancer. (2013) (0)
- PO-487 Prognosis of triple negative breast cancer is associated with MHC II genes (2018) (0)
- oubie-blinded study of normal indivi (1978) (0)
- IMMUNE RESPONSE TO INTRAMUSCULAR OR INTRAVENOUS CEA POLYNUCLEOTIDE IMMUNIZATION IN LARGE ANIMAL MODELS (1995) (0)
- Recent major breakthrough announced by U-M's growing clinical research faculty. (1981) (0)
- Abstract 5496: Cetuximab induces synthetic lethality with the poly (ADP-Ribose) polymerase (PARP) inhibitor ABT-888 in head and neck cancer (2011) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Albert F. Lobuglio?
Albert F. Lobuglio is affiliated with the following schools: